Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147,179,178
-
Total 13F shares
-
127,929,251
-
Share change
-
+869,257
-
Total reported value
-
$2,607,162,085
-
Put/Call ratio
-
58%
-
Price per share
-
$20.38
-
Number of holders
-
222
-
Value change
-
+$11,750,487
-
Number of buys
-
114
-
Number of sells
-
90
Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q4 2024
As of 31 Dec 2024,
Denali Therapeutics Inc. - COMMON STOCK (DNLI) was held by
222 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
127,929,251 shares.
The largest 10 holders included
BlackRock, Inc., BAILLIE GIFFORD & CO, VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, FMR LLC, Capital Research Global Investors, Temasek Holdings (Private) Ltd, STATE STREET CORP, Crestline Management, LP, and BAKER BROS. ADVISORS LP.
This page lists
222
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.